SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " GLP-1 " 304 found 🔀 AI-powered Shuffle
Ozempic and Wegovy linked to rare risk of sudden vision loss
Popular diabetes and weight loss drugs such as Ozempic and Wegovy have been linked to a slightly increased risk of a rare condition that can cause sudden, potentially permanent vision loss. Although the risk remains very low, Rutgers researchers say the findings warrant attention as millions of people turn to GLP-1 medications.
GLP-1 Users Face a Health-or-Wealth Choice
51% of GLP-1 users worry they may have to choose between medication and retirement savings. See what The Harris Poll found for Nationwide.
Popular weight loss drugs linked to a surprising fingernail problem
Popular GLP-1 weight loss drugs, such as Ozempic and Wegovy, have been linked to unexpectedly high rates of nail detachment, hair loss, and scalp inflammation, with some problems occurring several times more frequently among users. Researchers found that weight loss alone could not fully explain the differences, suggesting there may be more to these overlooked symptoms.
How ‘people power’ and business transformed medicine, but created a whole new set of risks
We’re seeing what happens when consumer demand collides with commercial interests for drugs including GLP-1s, psychedelics and testosterone. It’s a huge shift.
Ongoing lawsuits allege GLP-1s can cause serious harm. But we don't know how often
Scant data about serious adverse effects makes it harder to answer scientific and legal questions about how often the drugs might cause serious harm like blindness or pancreatitis.
Sami Inkinen, Virta Health CEO: A Fortt Knox Update
Virta Health CEO Sami Inkinen said the company posted its first-ever profitable quarter — Q2 2026, on cash-flow and EBITDA — after a post-2021 down round, part of a "Project Independence" push to self-funding. In conversation with Jon Fortt, he casts GLP-1 drugs as a tailwind: with nutrition, Virta says patients lose a third more weight (20% vs 15%) and sustain 85% of the weight loss a year after stopping, saving ~$5,600 per diabetes patient yearly. Virta serves ~800 employers and plans.
GLP-1s: the science behind today’s weight-loss drugs
The medicines reshaping obesity treatment grew out of research into how the body handles a meal. Long before weekly weight-loss injections became familiar, scientists were studying signals that travel from the intestine to the pancreas, helping it release insulin when nutrients arrive.
People on weight-loss drugs report fingernails falling off as researchers uncover surprising link
Nail discoloration was reported by 46% of GLP-1 users versus 17% of non-users, while scalp inflammation accompanied hair loss in most medication users studied.
Health spending at state’s top insurer surged 12%, led by GLP-1s
Healthcare spending growth at the state’s largest commercial insurer surged by nearly 12% in fiscal 2025, according to a new study that offers a jarring account of healthcare affordability wo…
HOMETOWN HEALTH: How to keep the weight off after stopping GLP-1 drug
Many people rapidly regain weight after stopping GLP-1 weight loss drugs
GLP-1 Drugs? Surgery? WHO Issues Guidelines For Obesity In Children
The World Health Organization (WHO) released its first-ever guidelines to address how clinicians should manage obesity in children and adolescents, which
WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight
The World Health Organization on Wednesday recommended diet, exercise and counseling over popular weight-loss drugs in its first global guidelines addressing rising obesity among younger children.
Study: How GLP-1 meds used to treat sleep apnea may affect oral health
“We need to understand how these medications affect the mouth so we can identify potential problems early and make sure patients receive comprehensive care.”
Health conference to cover GLP-1 drugs, hormone therapy, youth sports
The Area Health Education Center (AHEC) will host its 42nd Annual Update in Medicine Conference.
Good Health Report: GLP-1 patient gets help from a nutritionist
Good Health Report: GLP-1 patient gets help from a nutritionist
GLP-1s Show Benefit For Kids With Type 2 Diabetes
By Ernie Mundell HealthDay ReporterFRIDAY, Oct 2, 2026 (HealthDay News) — A real-world study finds GLP-1 medications helped kids, teens and young adults with type 2 diabetes lose weight, as well as improve their blood pressure and blood sugar control. “Our results confirm that GLP-1 receptor ...
Rapid weight loss on popular drugs could ‘starve’ the brain, expert warns
Dr. Tommy Wood warns GLP-1 drugs like Ozempic and Wegovy can shrink brain tissue when caloric restriction cuts off vital energy the brain needs.
Who Will Win the 2026 Nobel Prize? Scientists Make Their Predictions
From GLP-1 pioneers to researchers who uncovered the genetic roots of narcolepsy, scientists reveal who they think could receive a call from the Nobel Committee this year.
A popular GLP-1 provider just made its weight loss medications cheaper
Mochi Health has lower starting prices for compounded semaglutide and tirzepatide, plus a new lab testing service designed to help patients monitor their health.
Guest article: When nutrition becomes an evidence-based intervention, capital follows
Health and nutrition positioning alone buys nothing. Investors want evidence that products work and a moat competitors can’t easily replicate
Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, study suggests
New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, makes a case for extending the indication for GLP-1 receptor ...
Health Brief: The business of treating Alzheimer’s
Plus: FDA takes aim at a major compounding pharmacy’s GLP-1 offerings
Health Brief: The business of treating Alzheimer’s
Plus: FDA takes aim at a major compounding pharmacy’s GLP-1 offerings
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
A legal feud unfolding in New York is putting a spotlight on the work of a business development veteran who is credited for pioneering one of biopharma’s hottest dealmaking mechanism: the China “NewCo” model. In a lawsuit originally filed in New York state court and recently moved to federal court, China’s Lepu Medical Technology has alleged that biopharma business development consultant Su Zhang, who was hired to help shop its GLP-1 weight-loss candidates to Western partners, engaged in corporate double-dealing and trade secret leaks. According to the complaint, while acting as Lepu’s primary dealmaking liaison for a group of obesity and metabolic disease drug candidates, Zhang was secretly double-dipping as the acting chief business officer for a direct competitor, BrightGene Pharmaceutical. “She never adequately disclosed the role, never sought Lepu’s consent, and never proposed any safeguard,” Lepu alleged in its complaint, which was filed in July after Zhang’s consulting firm, CoDevCo, sought certain transaction-based success fees from its angry customer through an arbitration process in Singapore. Lepu, the parent company of Lepu Biopharma, has asked Zhang to pay back its $500,000 retainer and disgorge all benefits she received during the alleged breaches of fiduciary duty, plus other damages and relief. The company has also requested the court grant injunctions to protect Lepu’s trade secrets. The ill-fated partnership officially kicked off in December 2024, when Lepu tapped CoDevCo as its “exclusive business development mechanism” to identify collaborators for the company’s drug candidates. According to Lepu’s complaint, Zhang personally negotiated and signed the agreement as managing director for CoDevCo, which used her home address. Before the Lepu deal, Zhang made a name following a short stint as the global head of business development for Hengrui Pharmaceuticals. It was during her tenure that Hengrui signed a landmark deal granting exclusive rights for a portfolio of GLP-1 assets to Hercules, which was at that time newly established by a group of private equity and venture capital firms. In addition to the regular upfront and milestone payments, Hengrui also gained an equity stake in Hercules, which later became Kailera Therapeutics. The Hengrui-Hercules deal opened a new paradigm, where a Chinese biopharma company spins off certain early-stage assets to investors for further development through the creation of a new company abroad. The “NewCo” model quickly came into vogue as it allows Western investors to access high-potential assets originating from China at an early stage while giving the Chinese licensors an opportunity to reap long-term benefits through equity stakes in the new firms. The NewCo model proved its value when Kailera staged a record-breaking $625 million IPO on Nasdaq this April, merely two years into the Hengrui deal. Related Kailera CEO 'knew we were in a good spot' before obesity biotech's record-breaking $625M IPO On her LinkedIn page, Zhang described her work at Hengrui as “[b]uilding team and capability from the ground up,” forming NewCo and major pharma partnerships worth billions of dollars. Lepu clearly wanted that kind of track record to help boost its own cardiometabolic portfolio, which includes a range of assets for obesity, Type 2 diabetes, fatty liver disease and muscle preservation during weight loss treatment. “Lepu’s pipeline is very valuable, but only if Lepu could secure the right international partner to expand into the overseas market during the available commercial window,” the company argued in its complaint. The Chinese biotech said it had little knowledge of U.S. laws, customs or business practices in the business development field, and therefore “needed to rely entirely” on the expertise of Zhang and her team as the firm’s first engagement of a U.S.-based BD consultant. “Zhang’s dominating influence on the business development strategy is further evidenced by the fact that she personally controlled the business-development communications on behalf of Lepu with potential partners,” Lepu said in its complaint. After entering the deal, Zhang introduced Lepu to her four associates. According to Lepu’s version of events, all of them were allegedly employed at different time points to perform similar jobs at other Chinese companies that Lepu described as its competitors, while having access to Lepu’s confidential information. As such, Lepu described Zhang’s team as “a roster of individuals whose primary professional loyalty, by virtue of their concurrent full-time employment, ran to Lepu’s competitors.” As well as the specific examples set out in the case, a look at Lepu’s deals over the period suggests Zhang may have been involved in at least one transaction. During their partnership, Lepu, through its subsidiary Shanghai Minwei Biotechnology, also out-licensed its GLP-1/GIP/FGF21 agonist MWN105 to a NewCo called Sidera Bio in the fall of 2025. The deal included an upfront and near-term payment of $35 million, up to $1.01 billion in milestones, and a 9.99% stake in the Danish startup. It seems likely that Zhang facilitated the Minwei deal given that Lepu is on record as having used CoDevCo as its “exclusive business development mechanism.” The big shock for Lepu came in the form of a news article on June 25, 2025. The article, reporting on phase 2 data for BrightGene’s GLP-1/GIP receptor agonist BGM0504, identified Zhang as acting chief business officer of the Lepu rival. Blindsided by her association with BrightGene, Lepu confronted Zhang in July 2025. “Lepu was given assurances that there was nothing to be concerned about and told that Zhang would explain the matter to Lepu,” Lepu alleged in its complaint. “Zhang never did.” Lepu claimed that Zhang had the motive and opportunity to steer potential prospective partners toward BrightGene or other competitors. Later, in February 2026, one of Zhang’s associates joined BrightGene as the vice president for global business development, according to the complaint. Around the same time, Lepu sent written demand letters asking Zhang to account for her BrightGene role, identify what confidential data were shared with the rival firm, and provide any conflict-of-interest or firewall policies during the engagement. According to Lepu, neither CoDevCo nor Zhang answered the questions in their responses. Related Novo vs. KBP: How a $1.3B deal turned into a fraud accusation and an international legal fight In a motion to dismiss filed with the U.S. District Court in the Eastern District of New York on Sept. 4, Zhang’s legal team argued that Lepu’s agreement was signed with CoDevCo, and that an employee of the contractor does not owe fiduciary duties to the client. In its complaint, Lepu said: “That CoDevCo was the contracting entity does not insulate Zhang from personal liability for duties she personally undertook and personally breached.” Taking the argument one step further, the defending party argued that the consulting agreement “does not create a fiduciary relationship even between CoDevCo and Lepu; instead, it identifies CoDevCo as an independent contractor retained to market Lepu’s business to potential western partners.” Although CoDevCo was Lepu’s exclusive business-development contractor, there were no terms stipulating that the consulting firm should serve only Lepu, Zhang’s lawyer noted. As to Lepu’s claims that Zhang misappropriated trade secrets, the defendant argued that Lepu authorized the use of the information so Zhang’s team could perform their service per the agreement. In a rebuttal filed on Sept. 11, Lepu’s lawyer set out why they believe the Chinese biotech satisfied New York law’s misappropriation definition by alleging that the defendant used a trade secret “in breach of a duty or through improper means.” As an alternative to dismissing the suit, the defendant suggested the action should be stayed pending outcomes from the arbitration of a separate case in Singapore. While NewCo pioneer Zhang is defending her business arrangements, momentum behind the NewCo trend has continued unabated into 2026. Through August, Chinese biotech assets have spurred 15 NewCo deals this year, according to local trade publication PharmaDJ.
MORNING BUSINESS REPORT: Mortgage rates soar, rising vacation costs, McDonald's vs GLP-1 users
Mortgage rates rise again, families navigate high vacation costs, and McDonald's looks to attract GLP-1 users. Here's the Morning Business Report for Sept. 25.
FSU HEALTH COMMUNICATION EXPERT FINDS GLP-1 USERS FACE STIGMA WITHIN THEIR SOCIAL CIRCLES
Sept 24 2026 – People taking popular GLP-1 medications such as Ozempic, Wegovy and Zepbound may face stigma from those closest to them, according to a new study by a Florida State University professor. Braidyn Lazenby, an assistant professor at FSU’s College of Communication & Information, led the study “‘They Call Us Cheaters:” Exploring Stigma […]
FSU Health Communication expert finds GLP-1 users face stigma within their social circles
People taking popular GLP-1 medications such as Ozempic, Wegovy and Zepbound may face stigma from those closest to them, according to a new study by a
There’s a Limit to How Much GLP-1s Can Do, According to a New Study
New research suggests the lifestyle perks may be overblown.
Is 50 the new 60?
Subscribe TL;DR: Younger generations are showing signs of worse health compared to earlier-born cohorts at the same age This backward “drift” is showing up both in mortality risk and chronic disease Worsening trends in obesity and diabetes are the most consistent signals Taking the long view, we’ve made astonishing gains in health and life expectancy in the last century. Global average life expectancy has more than doubled from 32 years in 1900 to 73 years in 2024. (But don’t forget, there were still old people when life expectancy was 32). As people lived longer, they also generally lived healthier along the way. It turns out that avoiding things that can kill you early, like malnutrition and lots of childhood infections, also keeps you healthier later in life. In a classic 2004 paper, Finch and Crimmins proposed that cohorts of children who benefited from fewer early life infections had less lifetime exposure to inflammation and cardiovascular disease later in life, accelerating mortality improvements at older ages. Poor nutrition in the womb has also been linked to a higher risk of later chronic disease. The upshot is that improvements in childhood health can pay dividends many decades later. The combination of better living conditions (nutrition, sanitation) and medical advances (antibiotics, vaccines, blood pressure meds, etc) meant that people’s healthy lifespan generally expanded, even as they lived longer. Aging researchers call this best-case scenario “compression of morbidity”—meaning we delay the onset of disease and disability even faster than the years of life we are adding. During my 20+ year research career, we could generally bank on the idea that younger generations would not only live longer but also keep getting healthier along the way. “60 is the new 50” as they say… Enter “Generational Health Drift” Sadly, this expectation of steady progress may be changing. You’ve probably heard that US life expectancy gains have slowed to a crawl in the past couple of decades. Mortality improvements are also slowing (though less dramatically) in many other high-income countries (you can read more about that in a review paper I wrote here). Mortality is a very blunt health measure, but it is often a good barometer for the broader population health trends happening underneath. And we are now seeing that younger generations may be in worse health at similar ages compared to earlier born cohorts. My collaborator Prof. George Ploubidis at University College London coined this worsening health in more recently born cohorts “generational health drift.” “Generational health drift” is bad news on multiple fronts. Most obviously, we don’t want our health progress to go backward. But the timing is also bad, since our populations are aging. In demographic terms, “population aging” means that the proportion of the population at older ages (i.e >65 years) is increasing. Fun demography fact: Current population aging is not due to the recent declines in the birth rates making the news, but declines in fertility decades ago, after the “baby boom.” As baby boomers reach older ages, the smaller cohorts behind them mean the percentage of older adults will increase. For example, the share of the population age 65 and older in the US increased from 12.4% in 2004 to 18.0% in 2024. This story of population aging was written long ago. Many worry that population aging will put pressure on health care and pension systems. But if people reach older ages in better health than in years past, those fiscal pressures would be less dire than projected. Healthy older people can also continue to contribute to society in many valuable ways, including paid work, caregiving, community service….even high political office 🤷. On the flip side, if younger generations reach retirement age in worse health and with more disabling conditions, this could magnify the societal challenge of population aging. Evidence for worsening generational health A recent paper that I LOVED in the Proceedings of the National Academy of Sciences by Dr. Leah Abrams and colleagues examined which birth cohorts (aka generations) were behind worsening US mortality. Behold the Lexis diagram (cue swooning demographers). Calendar time is on the x-axis, age on the y-axis. Birth cohorts can be followed over time as they age on the diagonal lines moving up and to the right. This figure plots the year-on-year % change in all-cause mortality at a given age. Green shading indicates mortality improvements over time, white is stagnation, and gray shading indicates worsening mortality. Following the diagonal line for those born in 1950, you can see a noticeable shift from green to gray that follows this cohort for most of their lives. This gray shading shows generally worsening mortality for the 1950 to 1959 birth cohorts compared to their predecessors across all ages. Concerningly for my GenX and elder millennial peeps, there was also a deterioration in mortality for birth cohorts born in the 1970s and 1980s, visible as dark gray areas at ages 30 to 45 during the 2010s. While some of these mortality changes reflect specific shocks such as the opioid epidemic, most deaths still occur from major causes of death such as cardiovascular disease and cancer. For cancer, the gray in the top left corner of the figure below reflects the legacies of smoking for older cohorts, followed by a period of green with improvements in cancer mortality as smoking rates declined. But the white/gray shading in the bottom right corner highlights a stagnation and reversal of the cancer trends, with cohorts born around 1970 to 1985 experiencing worsening cancer mortality. This deterioration was most noticeable for colon cancer mortality, possibly linked to obesity or dietary factors. Not just dying more, but less healthy along the way. A recent paper by Dr. Laura Gimeno of University College London (of which I am a co-author), found evidence that more recently born cohorts in Great Britain have stagnating or worsening health. A stylized picture of what“generational health drift” might look like: The review paper found: Rates of childhood overweight and obesity were highest among Gen Z. Rates of diabetes in the 40s almost doubled from 3.1% among the Baby Boomers to 5.9% in Generation X. Gen Z reported higher rates of poor mental health in adolescence compared to earlier-born groups. These UK results are consistent with studies showing worsening health across generations in the US as well. A 2021 US study found that more recently born cohorts had worse biological markers (like blood pressure and blood sugar) than earlier generations at the same age. A separate 2022 study of Americans aged 50 and over found that more recently born generations had a higher number of chronic diseases, with younger age of disease onset. A 2024 Lancet paper found that in the US, women born in 1945 had 33% obesity prevalence at age 50, rising to 48.2% for women born in 1970 turning 50. So what’s going on, and can we turn it around? We don’t have a definitive answer for what’s causing the deteriorating health of younger cohorts, but circumstantial evidence points to worsening trends in obesity and diabetes in both the US and UK. Remember that cohort trends reflect lagged effects of early environments, and younger generations have faced both earlier onset and more severe obesity across their lifetimes. Despite these very concerning trends, the future is not set in stone. We’ve reversed poor generational health trends before: drops in smoking are a major reason cancer and heart disease deaths fell so dramatically in recent decades. GLP-1 drugs may finally turn the tide against rising rates of obesity and diabetes, though it is still early days. But things could also get worse…for example from a return to higher levels of childhood infectious diseases that can have a lasting impact on health. See for example: [ ](https://jenndowd.substack.com/p/dont-you-forget-about-measles-the) [ Don’t You Forget About Me(asles): The Virus That Erases Immune Memory ](https://jenndowd.substack.com/p/dont-you-forget-about-measles-the) Jenn Dowd, PhD · March 24, 2025 [ Read full story ](https://jenndowd.substack.com/p/dont-you-forget-about-measles-the) Even as an optimist, emerging data on the “generational health drift” has my full attention. For most of my research career, we took it for granted that each generation would be healthier than the last. But if present trends continue, **50 could be the new 60….**and Gen Z celebrities will soon look older than Paul Rudd :). Stay well, Jenn Share the Health! If you found this post useful, please share it with a friend. Share
How GLP-1s Are Reshaping the Business of Healthcare
John Teasley, Market Executive, Wells Fargo Healthcare Banking joins Good Day DC.
JB Pritzker Says He Used GLP-1s to Lose 80 Pounds
Gov. JB Pritzker of Illinois, widely seen as a potential presidential candidate, revealed in an interview on “CBS Mornings” that he had been on a GLP-1 regimen since 2024.
Scientists Discover New Compound That Burns Fat Without Killing Your Appetite
Unlike GLP-1 drugs, which suppress appetite and reduce energy intake, a newly identified molecular compound helps cells burn more energy without changing food intake or exercise and has shown promise in mouse models. The most successful new obesity drugs largely work by helping people eat less. Researchers at UC Berkeley are exploring a different strategy:
Health insurers covered 112,000 fewer Mass. residents’ GLP-1 weight-loss drugs this year, report finds
Insurers restricted coverage for obesity after years of financial losses.
GLP-1 drug slows aging in mice
A GLP-1 drug extended lifespan and prevented age-related decline in older female mice.
How $500 explains Republican health policy, and the GLP-1 Rx wave
The one health care policy Republicans agree on, and a look at how rural providers are approaching AI.
The weight I lost with GLP-1s came back 'with taxes' — how I finally dropped 100 lbs and kept it off
Kentucky looks to expand GLP-1 drug access for Medicaid patients
A federal program could help Kentuckians on Medicaid get GLP-1 drugs, but outdated state rules block the path.
Interra Health Adds GLP-1 Bridge Program Support
Interra Health is helping Medicare patients access $50-per-month GLP-1s through the new Bridge program.
Elevance leads UBS health benefits survey as employers brace for higher costs
UBS benefits survey ranks Elevance top insurer as 77% of employers rebid 2027 plans; GLP-1 costs surge and big PBMs stay strong—read now.
Bone Health Without the Hype
I am at the Australasian Menopause Society meeting and we had a fantastic lecture on Bone Health on Day 2, called, “Everything you need to know about bones - except the boring bits!” Spoiler alert, there were no boring bits. The lecture was given by Dr. Amanda Beech, who is a senior staff specialist in Obstetric Medicine and Endocrinology at the Royal Hospital for Women, where she is director of the Bone Density Unit. I want to summarize my top 10 take-aways for you. Share Osteoporosis is a disease of low bone mass, disruption of bone microarchitecture, and fragility of the skeleton. It is a silent disease…until someone develops a fracture. The diagnosis of osteoporosis is based on either fragility/minimal trauma fractures or a T-score of less than -2.5 on a DXA (Dual-Energy X-ray Absorptiometry) or bone scan. It is important to recognize that about 50% of minimal trauma fractures occur when women have low bone mass (often referred to as osteopenia), but not osteoporosis. This tells us that bone strength is more complicated than a number on a DXA report. I am going to add a little here that wasn’t in the talk (one can only include so much in 25 minutes), as many women might read the above paragraph and think, “Shouldn’t we be treating everyone with low bone mass if this is when 50% of the fractures occur?” Many fractures happen for women with low bone mass because there are so many women with low bone mass –it is a statement about the population on a whole, not about the fracture risk of low bone mass. For you as an individual, bone density is only one component of fracture risk and many women with lower bone mass will not have a significantly elevated fracture risk. This is why individualized risk assessment matters. Subscribe We build bone in our teens and twenties, and by the time we are about thirty we have reached peak bone mass. This is why, when we discuss risk factors for osteoporosis, it is important to consider factors that might have affected us in our teens and twenties when we were actively building bone, such as nutritional restriction/energy imbalance. It is important to ask women about a history of eating disorders, and for those with such a history, getting a bone scan in perimenopause or at age 50 is likely warranted. (This image below isn’t from the talk, but is similar to one that was). Bone mass is relatively stable until about two years before the final menstrual period, and perimenopause marks a time of rapid bone loss for women. Using urinary markers of bone loss we know that the time of significantly accelerated bone loss starts about 1 year before the final period and ends about 2 years after the final period. The Study of Women’s Health Across the Nation (SWAN) shows that over the menopause transition women lose an average of 10.6% of the bone at their lumbar spine and 9.1% at the femoral neck While this wasn’t covered in the lecture, I want to add that the rapid bone loss during perimenopause is clearly related to more than estradiol, because during this time estradiol levels can be erratic and not uniformly low. Bone loss during perimenopause is likely a multi-hormone event. For example, rising FSH (follicle stimulating hormone) tracks with bone loss better than estradiol, and there is evidence that FSH may act directly on bone. While decreased estrogen matters, there is clearly more going on. FSH and bone is an active area of research. Subscribe Screening for osteoporosis was recommended fairly broadly before age 65, and was taken from the “Practitioner’s Toolkit for Managing Menopause,” from Monash University. Here is a screenshot from the toolkit that was used as a slide: I am going to add a little bit more about body weight here for clarification. Low body mass (typically 152.1 lb): 0 points (risk neutral) 60–69 kg (132.3–152.1 lb): 3 points (adds some risk)
Scientists find Ozempic may slow aging itself
Semaglutide helped older healthy mice live longer while improving memory, muscle function, blood sugar control, and several biological signs of aging. Its effects went beyond those seen with calorie restriction, raising the possibility that GLP-1 drugs could tap into a separate biological pathway linked to longevity.
Meant Health Expands Telehealth Access to FDA-Approved GLP-1 Prescriptions, Including Ozempic®
Meant Health, a digital health platform that connects patients with licensed clinicians for evaluation, prescription and ongoing care coaching, announced today that it is expanding telehealth access to FDA-approved GLP-1 medications. The move is meant to shorten the distance between someone wondering whether a treatment might be right for them and an actual conversation with a U.S.-licensed clinician who could review their history and make that call.
From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weight loss jabs
Do you gain weight once you stop using them? Do they make your face saggy? Can they improve your mental health? Experts explain whether 13 common beliefs about GLP-1s are true or false
Interra Health now supports CMS’ GLP-1 Bridge Program
Electronic prescribing platform Interra Health announced Tuesday that it now supports the U.S. | Interra Health’s platform alerts providers when patients may be eligible to enroll in the program, executives say.
Lilly’s GLP-1 Windfall to Fund Investments in Women’s Health
The pharmaceutical giant has been assembling experts and hunting for new medicines across conditions including bone health and endometriosis, sources told Bloomberg.
Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets
Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and leading to debates over pricing and coverage. Learn how your company can be both patient-forward while also maximizing revenue in this unique environment.
Telemedicine company offers GLP-1s for addiction
A CDC Covid restructuring, public trust in Fauci, and more health news from Morning Rounds
Ozempic and Wegovy may have an unexpected mental health benefit
Semaglutide, the drug behind Ozempic and Wegovy, may have benefits that extend well beyond weight loss and diabetes. In a large Swedish study of nearly 15,000 people with bipolar disorder, its use was linked to a 21% lower risk of psychiatric hospitalization. Researchers think effects on inflammation and brain-related biological pathways could help stabilize mood, though other GLP-1 drugs did not show the same association.
An administrative gap delays access to new pancreatic cancer treatment
A new wave of illegal fruity vapes, more and more kids on GLP-1s, and other health news from Morning Rounds
Ozempic and GLP-1 agonists: Science magazine analysis
Science magazine analyzes the widespread use of Ozempic and GLP-1 agonists, warning of the risk of increasing social inequalities and calling for WHO intervention.
Cravings ‘like heroin withdrawal’: what happens when weight-loss drugs don’t work?
GLP-1 medications have been a gamechanger in the fight against obesity. But for a minority of patients, their impact is negligible. Why?
NC Medicaid, State Health Plan strategies diverge on GLP-1 coverage
More than 34,500 Medicaid beneficiaries had $47.9 million in weight-loss GLP-1 claims in June, while State Health Plan coverage remains limited.
Bonus Features – September 6, 2026 – 59% of clinicians say TikTok is the top source of misinformation about GLP-1s, AMA names leader for new Center for Digital Health and AI, plus 32 more stories
Welcome to the weekly edition of Healthcare IT Today Bonus Features. This article will be a weekly roundup of interesting stories, product announcements, new hi
The GLP-1 Squeeze: How Soaring Healthcare Costs Are Forcing Employers to Act
New survey results from the consultancy firm Marsh released last week show that employers expect per-employee health benefit costs to increase 8.2% on average in 2027—which would be the highest jump since 2003.
Health insurance costs are projected to rise by most in more than 20 years
The 2027 projection would mark the fifth consecutive year of elevated health benefit cost growth after a decade of more moderate annual increases. It would also be the sharpest increase during the five-year period, up from a projected 6.7%…
Health benefit costs to jump 8.2% in 2027, highest since 2003
Marsh survey finds GLP-1 drugs, AI billing, and No Surprises Act disputes are each adding a full percentage point to trend
Rising costs of health benefits: Total cost per employee expected to rise 8.2% in 2027
Joseph Kra, Marsh senior partner and northeast health zone practice leader, joins 'Squawk Box' to discuss the rising costs of health benefits, impact of GLP-1s on health benefit costs, and more.
GLP-1 smuggling means big business for Brazil’s black market
With 5.5% of Brazil’s population using GLP-1s, smugglers are profiting from the illegal movement and sales of medication
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia
Telehealth company Hims & Hers said on Monday it has begun offering branded GLP-1 weight-loss drugs and other treatments to men in Australia as it continues to expand its international business.
GLP-1 drugs are almost single-handedly forcing employers to reconsider workers' health care
Another hospital system sues CVS Health, how Medicaid cuts will change everything, and more
Together, GLP-1s And GenAI Can Solve Healthcare’s Affordability Crisis
Two innovations offer a new path to healthcare affordability: GLP-1 medications and generative AI. Here's how to two could radically improve medicine and lower costs.
Medicare's pilot GLP-1 discount program has a catch. Some sick patients don't qualify
Medicare launched a pilot program that could streamline the process to get GLP-1s, with some seniors paying just $50 a month. But many people with the most serious illnesses won't get that discount.
Why some companies may not be offering coverage for GLP-1 weight loss drugs
Some companies have said they are no longer offering health insurance coverage for GLP-1s for weight loss. Experts say this may be a "business decision."
FDA approves tirzepatide for reducing cardiovascular risk in adults with type 2 diabetes
The popular drug, sold by Eli Lilly and Company under the brand name Mounjaro, has been at the center of many cardiology trials over the years. It is now the first dual GIP and GLP-1 hormone receptor agonist approved by the FDA for this indication.
Dolly’s generosity to Vanderbilt Health highlighted; reading test results before your doctor has a chance; staying healthy this fall; plus other stories with Vanderbilt Health sources
Dolly Parton’s generosity to Vanderbilt Health was mentioned in many of her obituaries. A sampling: The New York Times, the BBC, NPR, NBC News, The Guardian, and Scripps News. Vanderbilt Health News posted a tribute to her, as well, and Mark Denison, MD, Professor Emeritus of Pediatrics and former director of the Division of Pediatric Infectious Diseases, spoke to NewsNation for a story about her impact on his research. Everyday Health interviewed Trent Rosenbloom, MD, MPH, Professor of Biomedical Informatics, for a story about a new JAMA study that found two-thirds of patients read test results before connecting with a doctor. Comprehension of test results varied: 6.6 percent said they had a poor understanding, 26.8 percent understood the results fairly well, 31.7 percent understood them well, and 34.9 percent understood the results very well. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: Healthline (cyclosporiasis cases now in 47 states); “The Naked Scientists” podcast (salmonella outbreak sickens hundreds); Medscape (the lighter-than-usual just-completed Australian flu season); and People (how to stay healthy this fall). Scripps News interviewed Jessica Young, MD, Associate Professor of Clinical Obstetrics and Gynecology, about Vanderbilt researchers launching a study to determine if GLP-1 drugs can help people with opioid use disorder. WSMV Channel 4 News reporter Diana Rocco interviewed Kashish Goel, MBBS, Associate Professor of Medicine and Director of Transcatheter Heart Valve Interventions, for a story about patient Dixie Watt and her minimally invasive valve replacement with the M3 device, the first Food and Drug Administration-approved transseptal transcatheter mitral valve replacement. Fogarty International Center writer/editor Susan Scutti interviewed John Koethe, MD, Associate Professor of Medicine, Division of Infectious Disease, for a profile article for their newsletter, Global Health Matters. The article presents him as an example of a Fogarty Fellow success story and focus on his past and present research, including the HIV/AIDS research he conducted for his Fogarty project at the Centre for Infectious Diseases Research in Zambia in 2008 and 2009.
GLP-1s may have a host of other health benefits. Just ask these people
Here is what scientists currently know about GLP-1s, and where hype may be getting ahead of the evidence.
Can California help lower the cost of GLP-1s? Here’s what lawmakers are proposing
An LA-area Democrat wants California to partner with drug manufacturers to make weight loss drugs cheaper — drawing on her own experience paying out of pocket.
GLP-1 Benefits Beyond Weight Loss: Heart Health, Lower Cancer Risk And More
Doctors say GLP-1 drugs seem to have “profound benefits” beyond weight loss and diabetes. Some wonder whether they can help people live longer, but stress need for more research.
More US employers to drop weight-loss drugs in 2027, as healthcare costs increase
About 14% of employers in the United States have already or plan to drop GLP-1 drugs in 2027, as companies see rising healthcare costs, according to a survey released on Tuesday by the Business Group on Health.
More US Employers to Drop Weight-Loss Drugs in 2027, as Healthcare Costs Increase
By Amina Niasse NEW YORK, Aug 25 (Reuters) - About 14% of employers in the United States have already or plan to drop GLP-1 drugs in 2027, as companies see rising healthcare costs, according to a survey released on Tuesday by the Business Group on Health. Healthcare costs are set to increase ...
One Type of Diabetes Responds Better to a Weekly GLP-1 Drug Than to Insulin
GLP-1 wins again.
Experimental compound helps burn fat without muscle loss
A decades-old compound may point to a new way of treating obesity by making the body burn more energy rather than simply reducing appetite. In mice, TOFA increased energy use by as much as 18%, reduced body fat without significant muscle loss, and improved blood sugar, triglycerides, and fatty liver disease. It also produced stronger results when combined with GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound.
Employer healthcare expenses could spike 9.5% in 2027, pressured by GLP-1s
The benefits management company Aon said per-employee expenditures may rise about $19,000. While the broader economy is to blame, part of the rise can be attributed to the management of costly chronic conditions such as diabetes.
New study raises concerns over use of weight-loss drugs in elite sport
Researchers surveyed 114 sports medicine physicians from 38 countries, covering 93 different sports, to explore their views on athletes' use of GLP-1 drugs. Twelve percent said they were aware of athletes ...
Cancer doctor reveals 5 habits that may reduce disease risk and improve outcomes
A breast surgical oncologist shares five everyday strategies to reduce cancer risk, including how GLP-1 drugs like Ozempic could play a role.
Could GLP-1s help treat opioid use disorder? Vanderbilt Health study now enrolling
The study, Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB), is a double-blind, randomized, placebo-controlled trial conducted through the National Institute on Drug Abuse’s Clinical Trials Network.
Could a drug designed for weight loss help athletes perform better?
GLP-1 weight-loss drugs can reduce weight and improve health, but could they also boost athletic performance?
GLP-1 weight loss drugs may boost results but raise oral health risks, dentist warns
Scientists solve the mystery of a brain “switch” that can trigger weight loss in opposite ways
Scientists have uncovered why two seemingly opposite ways of targeting the same brain receptor can both promote weight loss. In mice, activating the GIP receptor in the brainstem reduced appetite, while blocking it in the hypothalamus removed a kind of “brake” on fullness signals. The discovery helps explain why very different obesity drugs can achieve similar results and suggests that carefully combining GIP-targeting treatments with GLP-1 drugs like those related to Wegovy and Ozempic could produce stronger effects.
People are injecting fat from dead bodies. It’s called ‘zombie filler’
People are injecting fat from corpses and calling it "zombie filler." Doctors say the GLP-1 boom is driving the trend.
Ozempic may have revealed the brain’s hidden “craving center”
Ozempic-like drugs appear to weaken more than hunger—they may also reduce cravings for alcohol and other addictive substances. Scientists are increasingly tracing this effect to the lateral septum, a brain region that helps connect memories and surroundings with rewarding experiences. Packed with GLP-1 receptors, it may act as a crucial control point between thinking about a reward and feeling compelled to pursue it. The discovery could open new approaches to treating addiction as well as obesity.
Chrissy Metz Talks '& Juliet' and New Music, Shares Health Update
Chrissy Metz, “This is Us” and “The Hunting Wives” star, joins TODAY to open up for the first time about her decision to use GLP-1 medication and announce her new partnership with health care company Ro. Metz details why she was originally skeptical around weight loss drugs, shares how the medication has improved her life, dishes on performing in “& Juliet” and teases new music in the works.
Chrissy Metz Reveals She’s Taking a GLP-1 Drug: EXCLUSIVE
The actor discussed the mental and physical changes she’s noticed since partnering with Ro.
Kylo Peptides Expands Research Catalog to 36 Compounds as Peptide Science Enters a Record Growth Cycle
US research-peptide supplier scales its catalog against a market that analysts value between $47 billion and $141 billion, as peptides hold near 10% of new FDA drug approvals and GLP-1 use among American adults doubles in 18 months.Sheridan, Wyoming, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides, a US supplier of research-grade peptides, has expanded its catalog to around 36 peptides and research blends, the company announced today. The milestone lands during the most active growth period in t
GLP-1s Like Ozempic, Mounjaro May Lower Fracture Risk in Type 2 Diabetes
A new study has found that GLP-1 medications, like Ozempic and Mounjaro, may help reduce the risk of fragility-related fractures in people with type 2 diabetes.
This Week in Science: Mosquito Magnets, Bonus Benefits of GLP-1s, And More
Our weekly science news roundup.
Health Watch: Watch what you eat during food illness outbreaks; GLP-1s may help with dementia
Fact vs. Fiction: Separating the Myths from the Science Behind GLP-1 Medications
From social media claims to questions about safety, UConn Health OB/GYN and obesity medicine specialist Dr. Jason Schneider explains what patients should re ...
CVS Health enhances its direct-to-consumer weight management offerings to improve access, affordability, care and support for GLP-1 medications
CVS Health® today announced a revamp of its weight management program, making it easier for eligible adults to access clinical care, navigate medication costs and get ongoing support for GLP-1 therapy.
As the GLP-1 Era Reshapes Weight Management, METAbiotics Launches with Science Designed to Support Long-Term Success
Today, Danone subsidiary The Akkermansia Company announced the U.S. launch of METAbiotics, a science-backed postbiotic brand developed from decades of pioneering research into Akkermansia muciniphila and designed to support sustained weight management and metabolic health.
For GLP-1 users, the in-store clothes shopping trip is back
Nora Nye, 58, is refreshing her wardrobe as she sizes down for the first time in over three decades after losing 80 pounds on weight-loss drug Mounjaro. Earlier this year, the Denver bankruptcy lawyer walked into a Macy's and found herself overwhelmed.
Hims and Hers accused of sharing GLP-1 patients' health data with Meta
The FTC conducted a nearly 3-year investigation before filing a lawsuit.
GLP-1s And Alcohol Addiction: Potential Benefits And What You Need To Know
GLP-1s And Alcohol Addiction: Potential Benefits And What You Need To Know
GLP-1s And Kidney Disease: Potential Benefits And What Experts Say
GLP-1s And Kidney Disease: Potential Benefits And What Experts Say
CASPR Ends Tenagrity Contract as Agenda Turns to Gambling
Center for Addiction Science terminates Tenagrity Solutions lobbying contract focused on GLP-1 drug access. Read the latest policy update.
GLP-1s can affect how often some people need to take time off work, study finds
An analysis of employees in Denmark finds that diabetics taking Ozempic had fewer absences from work.
FedEx is chasing the GLP-1 boom. Why healthcare logistics means big business
The push marks FedEx's latest move to bolster business-to-business healthcare shipping, one of the four B2B verticals the company has prioritized.
Some people are getting shut out when it comes to GLP-1 drugs. Here’s why.
People with obesity in the United States are being sorted between haves and have-nots.
‘Ozempic face’ and hair loss: what evidence is there for weight-loss drug side-effects?
Research into GLP-1 medications is not always robust but complaints such as digestive problems are well known